SMO突变状态定义嗅沟脑膜瘤中一个独特且常见的分子亚组
该研究用Sanger测序检测79例嗅沟脑膜瘤的SMO(L412F和W535L)与AKT1E17K突变,并回顾临床资料评估预后价值。34例(43%)存在可靶向突变,其中SMO突变22例(28%)、AKT1突变12例(15%)。SMO突变组总体复发率36%,显著高于AKT1突变组(16%)和SMO与AKT1野生型组(11%)(χ2检验,P = .04)。
要点
- 79例嗅沟脑膜瘤中34例(43%)存在可靶向突变,SMO突变22例(28%),AKT1突变12例(15%)。
- SMO突变组总体复发率36%,高于AKT1突变组的16%和SMO与AKT1野生型组的11%(P = .04)。
- 所有晚期复发(5年后)均发生于SMO突变组。
核心结论
- SMO L412F/W535L与AKT1 E17K突变的分子诊断可改善嗅沟脑膜瘤的预后评估,并为复发 case 使用SMO或AKT抑制剂提供新的治疗前景。
研究设计与样本
- 采用Sanger测序技术对79例嗅沟脑膜瘤样本进行SMO(L412F和W535L)与AKT1E17K突变检测,并回顾临床资料评估这些突变在该解剖亚组中的预后价值。
主要发现
- 79例嗅沟脑膜瘤患者中,34例(43%)检出可靶向突变,其中22例(28%)为SMO突变(几乎均为L412F),12例(15%)为AKT1突变。
- SMO突变组总体复发率为36%,显著高于AKT1突变组的16%和SMO与AKT1野生型组的11%(χ2检验,P = .04)。
- 所有晚期复发(5年后)均发生于SMO突变组。
- 在WHO I级脑膜瘤中,SMO突变组被确定为预后显著更差。
- WHO组织学II级(P = .006)和不完全切除(P = .001)与更短的无复发生存期独立相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Meningiomas are the most common primary intracranial tumors in adults. Identification of SMO and AKT1 mutations in meningiomas has raised the hope for targeted therapies. It would be useful to know the precise frequency of these mutations in anatomical subgroups and clarify their prognostic value. METHODS: We used the Sanger sequencing technique to characterize 79 samples of olfactory groove meningiomas for SMO (L412F and W535L) and AKT1E17K mutations. We reviewed clinical data to assess the prognostic value of these mutations in this anatomical subgroup. RESULTS: Out of the 79 patients with olfactory groove meningiomas, we identified targetable mutations in 34 patients (43%) (22 patients [28%] with SMO mutation-L412F almost exclusively-and 12 patients [15%] with AKT1 mutation). Meningiomas in the SMO-mutant group had an overall 36% recurrence rate, significantly higher than in the AKT1-mutant group (16%) and in the "SMO and AKT1 wildtype" group (11%) (χ2 test, P = .04). All late recurrences (after 5 y) occurred in the SMO-mutant group. Among grade I meningiomas, the SMO-mutant group was identified as having a significantly poorer prognosis. World Health Organization histological grade II (P = .006) and incomplete resection (P = .001) were independently associated with shorter recurrence-free survival. CONCLUSION: Molecular diagnosis of SMOL412F/W535L and AKT1E17K mutations improves prognostic evaluation in olfactory groove meningiomas and opens new therapeutic perspectives with SMO or AKT inhibitors for recurrent cases.
引用
- Boetto J, Bielle F, Sanson M, et al. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas. Neuro Oncol. 2017. PMID: 28082415. doi:10.1093/neuonc/now276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。